Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
Volatility and Risk
Creative Medical Technology has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Creative Medical Technology and Kymera Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 0 | 0 | 0 | 0 | 0.00 |
| Kymera Therapeutics | 0 | 3 | 10 | 1 | 2.86 |
Institutional and Insider Ownership
1.4% of Creative Medical Technology shares are owned by institutional investors. 2.8% of Creative Medical Technology shares are owned by company insiders. Comparatively, 15.8% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Creative Medical Technology and Kymera Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $11,000.00 | 789.78 | -$5.29 million | ($3.80) | -1.31 |
| Kymera Therapeutics | $87.56 million | 23.19 | -$146.96 million | ($2.34) | -13.40 |
Creative Medical Technology has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Creative Medical Technology and Kymera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -63.05% | -60.42% |
| Kymera Therapeutics | -191.26% | -24.96% | -20.27% |
Summary
Kymera Therapeutics beats Creative Medical Technology on 10 of the 15 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
